Related Experiment Video
Updated: Jan 5, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
608
Active surveillance in intermediate-risk prostate cancer
1Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
BJU International
|October 25, 2019
Summary
Active surveillance (AS) is a viable option for select men with favorable intermediate-risk prostate cancer. Biomarkers and imaging help identify suitable candidates for this conservative management approach.
Area of Science:
- Oncology
- Urology
- Prostate Cancer Management
Background:
- Active surveillance (AS) is standard for favorable-risk prostate cancer.
- Selected men with favorable intermediate-risk prostate cancer may benefit from AS.
Purpose of the Study:
- Review indications for conservative management in intermediate-risk prostate cancer.
- Evaluate outcomes of AS in this population.
- Assess the role of biomarkers and imaging in candidate selection.
Main Methods:
- Review of prospective series on active surveillance outcomes.
- Analysis of indications for conservative management.
- Evaluation of molecular biomarkers and imaging for risk stratification.
Main Results:
- Intermediate-risk prostate cancer is heterogeneous, with some indolent and some aggressive cases.
- Traditional staging inadequately captures this heterogeneity.
- Clinical, genomic, and radiological biomarkers are crucial for accurate risk stratification and patient selection.
Conclusions:
- Active surveillance offers benefits and is an appealing option for carefully selected patients with intermediate-risk prostate cancer.
- Biomarkers and imaging are key to identifying optimal candidates for AS.
Keywords:
active surveillanceconservative managementintermediate riskprostate cancerrisk stratification
